All News

Dollar General’s expansion into health care space will include an increased assortment of cough and cold, dental, nutritional, medical, health aids, and feminine hygiene products in many stores.

This risk was not seen in older adults with dentures, which could indicate that the cognitive decline associated with tooth loss could be mitigated through timely and effective treatment with dentures, according to the investigators.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed what some of the adverse events experienced by patients were, and how patients were able to handle them.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the importance of the FDA’s expedited approval process for infigratinib in the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.

The keys to this recovery will be innovation and collaboration, according to Craig Dolan, PharmD, MBA, of McKesson RxO.

Study’s secondary endpoints were also met, including the achievement of endoscopic improvement, histologic-endoscopic mucosal improvement, and corticosteroid-free clinical remission at week 52.

Despite significant medical advancements related to HIV treatment and quality of life, the risk of suicide in patients is high and health care providers should prioritize mental health screenings in this population.

This risk decreased gradually according to age and length of time after an HZ episode, but epidemiological studies and the pathology of VZV vasculopathy both indicate that HZ is a key risk factor for stroke up to 1 year following an HZ episode.

A recent study proved community pharmacies are model settings for skin cancer prevention education in rural communities with insufficient access to health care services.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the research assessing dapagliflozin advanced from cardiorenal effects to prevention and organ protection.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed how the US FDA evaluated the application for infigratinib to expedite the approval process for treatment of previously treated locally advanced or metastatic cholangiocarcinoma.

Recurrent C. diff infections were observed in 16% of patients who received bezlotoxumab, compared with 29% of patients who received standard of care alone.

The drug is approved for patients after 4 or more failed lines of therapy, although many patients in clinical trials had received 7 or more prior lines of therapy.

New research presented at the ESMO World Congress on Gastrointestinal Cancer suggests the use of antibiotics may increase the risk of colon cancer, especially in individuals under age 50 years.

The 5-year overall survival was 18% in the CPX-351 group compared to 8% in the standard chemotherapy group.

Investigators have identified metabolic and glycomic signatures in blood samples of post-treatment controllers, a rare population of HIV-infected individuals who can naturally sustain viral suppression after antiretroviral therapy.

The study evaluated vaccination trends among adults aged 18 years or older using data from the CDC, comparing the rates in Ohio before and after the implementation of the lottery with states that did not have lottery programs.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

Health information technology is becoming available an accelerated pace, and it will take time to train individuals on how to effectively employ a new technology and convince them of its merit.

CEL-SCI Corporation plans to file for FDA approval in patients with advanced primary squamous cell carcinoma of the head and neck based on these trial results.

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses how the results from the phase 3 trial evaluating an investigational 2 mg dose of semaglutide could change treatment options for patients with type 2 diabetes.

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the dosing and treatment cycle during the trial assessing infigratinib for the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.

Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the results of the DARE-19 trial are important to the field, especially during the COVID-19 pandemic.

Other options for Crohn disease and ulcerative colitis include biologics, corticosteroids, immunosuppressants, and vedolizumab.

As the first point of contact at many pharmacies, technicians can often see whether a patient has been prescribed an opioid or other monitored substances.

The approval is based on results from the phase 2 KEYNOTE-629 trial, which found an objective response rate of 50% in adults with recurrent, metastatic, or locally advanced cutaneous squamous cell carcinoma.

The study authors said that these findings could be used to help identify healthy people who are at risk for the condition before they have symptoms.

Two studies by the University of Colorado Cancer Center provided an analysis for the theory of adaptive oncogenesis.